英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Janssen查看　Janssen　在百度字典中的解释百度英翻中〔查看〕
Janssen查看　Janssen　在Google字典中的解释Google英翻中〔查看〕
Janssen查看　Janssen　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home | Global Trial Finder
    Janssen Global Trial Finder; World Without Disease Accelerator; Janssen Clinical Innovation; Precision Medicine Janssen Diagnostics
  • Janssen | 2022 Transparency Report
    Through the 2022 Janssen U S Transparency Report, we continue our legacy of contributing insights, data and real-world evidence to help inform and advance policy solutions to create a more sustainable, equitable and innovative healthcare system
  • Janssen Submits New Drug Application to U. S. FDA Seeking Approval of . . .
    RARITAN, NJ, May 30, 2023 – The Janssen Pharmaceutical Companies of Johnson Johnson announced today the submission of a New Drug Application (NDA) to the U S Food and Drug Administration (FDA) seeking approval of an investigational single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M T STCT) for the long-term
  • A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of . . .
    The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML)
  • How can we help you today? - connect. janssen. com
    This website is published by Janssen-Cilag Pty Limited (Janssen-Cilag), which is solely responsible for its content It is intended for Global healthcare professionals Changes to your country will result in data loss
  • A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to . . .
    The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis
  • A Phase 1 2 Study of Bleximenib in Participants With Acute Leukemia
    The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion) The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D
  • A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting . . . - Janssen
    The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion)
  • Privacy Policy section - Janssen CarePath
    Janssen Pharmaceuticals, Inc , recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country
  • A Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide . . .
    The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with either daratumumab or pomalidomide; and for Part 2 (Dose Expansion) is to further define the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s)





中文字典-英文字典  2005-2009